These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 35195152)

  • 1. Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.
    Souza VG; Santos DJS; Silva AG; Ribeiro RIMA; Loyola AM; Cardoso SV; Miranda CSS; Cardoso LPV
    J Appl Oral Sci; 2022; 30():e20210344. PubMed ID: 35195152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
    Lopes MLDS; Gonzaga AKG; Mosconi C; Palomino GM; Mendonça EF; Batista AC; Silveira ÉJDD
    Arch Oral Biol; 2019 Feb; 98():99-107. PubMed ID: 30468994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
    Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
    J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and Therapeutic Implications of Immune Classification by CD8
    García-Marín R; Reda S; Riobello C; Cabal VN; Suárez-Fernández L; Vivanco B; Álvarez-Marcos C; López F; Llorente JL; Hermsen MA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin.
    Bauer C; Abdul Pari AA; Umansky V; Utikal J; Boukamp P; Augustin HG; Goerdt S; Géraud C; Felcht M
    Cancer Immunol Immunother; 2018 Jul; 67(7):1147-1157. PubMed ID: 29799076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
    Malaspina TS; Gasparoto TH; Costa MR; de Melo EF; Ikoma MR; Damante JH; Cavassani KA; Garlet GP; da Silva JS; Campanelli AP
    Cancer Immunol Immunother; 2011 Jul; 60(7):965-74. PubMed ID: 21442435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical Analysis of Foxp3
    Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
    Pathol Oncol Res; 2018 Jul; 24(3):497-505. PubMed ID: 28669079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical comparative analysis of IMP-3 and KI-67 in actinic cheilitis and lower lip squamous cell carcinoma.
    de Souza Martins Câmara AC; Gonzaga AKG; Dos Santos Pereira J; Queiroz SIML; da Silveira ÉJD; Pinto LP; de Souza LB
    Oral Maxillofac Surg; 2022 Dec; 26(4):587-593. PubMed ID: 34817714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
    Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
    Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
    Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T
    Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.